// App-Quantinova.ai

16741 : The Cost-Effectiveness of Apixaban versus Warfarin in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Study Group

Researchers

Presenter

  • Shubin Sheng

Principal Investigators

  • Kevin J Anstrom

  • John JV McMurray

  • P. Gabriel Steg

  • Hopital Bichat-Claude Bernard

  • John H Alexander

  • Christopher B Granger

  • Daniel B Mark

  • Judith A Stafford

  • Renato D Lopes

  • Linda Davidson-Ray

  • Lars Wallentin

  • Hemant M Phatak

  • Jack Ansell

  • Paul Dorian

  • Steen Husted

Medical Centers

  • Duke Clinical Res Inst, Duke Univ Medical Ctr, Durham, NC

  • Aarhus University Hospital, Aarhus, Denmark

  • New York, New York, NY

  • Duke Clinical Research Institute, Durham, NC

  • U Toronto, Toronto, ON, Canada

  • Western Infirmary and the British Heart Fndn Glasgow Cardiovascular Res Ctr, Glasgow, United Kingdom

  • Uppsala Clinical Res Ctr, Uppsala Univ, Uppsala, Sweden

  • ENS Paris, Paris, France

Locations

  • Canada

  • United Kingdom

  • United States

  • France

  • Denmark

  • Sweden

Companies

  • Bristol-Myers Squibb

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Arrhythmia

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • apixaban

  • Warfarin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved